Full Press Release Details
LEXINGTON, Mass.--(BUSINESS WIRE)--$AGEN#AGEN--Agenus Inc.(“Agenus”) (NASDAQ: AGEN), a leader in immuno-oncology innovation, today announced that its Annual Shareholders Meeting will begin at 10:00 a.m. ET on June 16, 2026, and will be conducted in a virtual format only. Registration for attendees will start at 9:45 a.m. ET.
To participate in the Annual Shareholders Meeting, shareholders should visitwww.virtualshareholdermeeting.com/AGEN2026and enter the 16-digit control number found in their proxy materials. Guests may also access the Annual Shareholders Meeting, but in listen-only mode. No control number is required for guests.
Webcast Information:
Date: Tuesday, June 16, 2026
Time: 10:00 a.m. ET
A live webcast and replay will be accessible on the Company’s website athttps://investor.agenusbio.com/events-and-presentationsand atwww.virtualshareholdermeeting.com/AGEN2026.
Voting Information:
Shareholders of Agenus as of the April 22, 2026, record date can vote. Alliance Advisors, Agenus’s proxy solicitor, can assist shareholders with voting at 844-202-6561 orAGEN@AllianceAdvisors.com.
About Agenus
Agenus is a leading immuno-oncology company targeting cancer with a comprehensive pipeline of immunological agents. The company was founded in 1994 with a mission to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants (through SaponiQx). Agenus has robust end-to-end development capabilities, across commercial and clinical cGMP manufacturing facilities, research and discovery, and a global clinical operations footprint. Agenus is headquartered in Lexington, MA. For more information, visitwww.agenusbio.comor @agenus_bio. Information that may be important to investors will be routinely posted on our website and social media channels.